Developer docs
API playgroundTry for free, no card

Search company profiles

ChitogenX

Full company profile

uuid0005v5e

Namestring
ChitogenX
Legal namestring
ChitogenX Inc.
Websiteurl
chitogenx.com
Company typeenum
Private
Founded yearint
2015
Short descriptiontext

ChitogenX Inc. is a clinical-stage orthopedic biotechnology company based in Quebec, Canada, developing a biologic therapy for rotator cuff tear repair. The company is pre-revenue, operating with 1-10 employees and is publicly listed on the CNSX under CHGX.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersQuebec, Canada
HQ citystring
Quebec
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
orthopedic biotechnology, tissue repair therapy, biologic therapy, rotator cuff treatment, clinical-stage biopharmaceutical
Industry1 code
1Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
CodeHLAHAEAGPrimaryYes
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Orthopedic Biologics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ChitogenX Inc. is a clinical-stage orthopedic biotechnology company developing a biologic therapy for rotator cuff tear repair. The lead asset is in Phase I/II clinical trials, with the company headquartered in Quebec, Canada and publicly listed on the Canadian Securities Exchange (cnsx:CHGX).

Differentiator
Functional benefit
Problem solved
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ChitogenX

Orthopedic Biologicschitogenx.com

ChitogenX Inc. is a clinical-stage orthopedic biotechnology company based in Quebec, Canada, developing a biologic therapy for rotator cuff tear repair. The company is pre-revenue, operating with 1-10 employees and is publicly listed on the CNSX under CHGX.

ChitogenX firmographics

Firmographics
Name
ChitogenX
Legal name
ChitogenX Inc.
Website
https://chitogenx.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
ChitogenX Inc. is a clinical-stage orthopedic biotechnology company based in Quebec, Canada, developing a biologic therapy for rotator cuff tear repair. The company is pre-revenue, operating with 1-10 employees and is publicly listed on the CNSX under CHGX.
Ownership category
akta.pro rank

ChitogenX industry classification

Industry
Product category
Orthopedic Biologics
NAICS
Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

Keywords

  • Orthopedic biotechnology
  • Tissue repair therapy
  • Biologic therapy
  • Rotator cuff treatment
  • Clinical-stage biopharmaceutical

Where ChitogenX is headquartered

Location

Headquarters

HQ city
Quebec
HQ country
Canada
HQ region
North America

Markets served

ChitogenX business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

ChitogenX product offering

Product offering

Core offering

ChitogenX Inc. is a clinical-stage orthopedic biotechnology company developing a biologic therapy for rotator cuff tear repair. The lead asset is in Phase I/II clinical trials, with the company headquartered in Quebec, Canada and publicly listed on the Canadian Securities Exchange (cnsx:CHGX).

Differentiator

Problem solved

Functional benefit

Companies that use ChitogenX

Customer profile

Ideal customer profiles1 record

ChitogenX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

ChitogenX partnerships and signals

Strategic signal

Scale indicators3 records

ChitogenX competitors and assessment

Company assessment

Market position

Customer concentration

ChitogenX social profiles

Digital presence

ChitogenX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ChitogenX leadership team

Management profile

Number of profiles

Profiles4 records

ChitogenX funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ChitogenX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ChitogenX

What does ChitogenX do?

ChitogenX Inc. is a clinical-stage orthopedic biotechnology company developing a biologic therapy for rotator cuff tear repair. The lead asset is in Phase I/II clinical trials, with the company headquartered in Quebec, Canada and publicly listed on the Canadian Securities Exchange (cnsx:CHGX).

Is ChitogenX a public or private company?

ChitogenX is a private company. It is classified as public and is currently operating.

When was ChitogenX founded?

ChitogenX was founded in 2015. It employs 1 to 10 people.

Where is ChitogenX based?

ChitogenX is headquartered in Quebec, Canada, in the North America region.

Does ChitogenX have an API?

No public API is recorded for ChitogenX.

What industry is ChitogenX in?

ChitogenX's product category is Orthopedic Biologics. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewswireCHITOGENX ANNOUNCES NEW $2.5 MILLION NON-BROKERED PRIVATE PLACEMENT OFFERING AND BALANCE SHEET RESTRUCTURINGChitogenX Inc. announced a new $2.5 million non-brokered private placement offering, replacing a previously terminated financing plan to restructure its balance sheet. The company simultaneously eliminated $5.6 million in short-term liabilities through the extension and partial conversion of debentures. Proceeds will be used to complete enrollment in its U.S. Phase I/II rotator cuff tear repair clinical trial.NewswireCHITOGENX ANNOUNCES $3.5 MILLION GRANT TO ADVANCE ORTHO-R COMMERCIAL DEVELOPMENTChitogenX Inc. has secured a $3.5 million grant from The Natural Sciences and Engineering Research Council of Canada (NSERC) and Prima Québec in partnership with Polytechnique Montréal. The four-year funding will support the scientific development and expansion of indications for its ORTHO-R regenerative medicine technology platform. This investment aims to accelerate the commercial readiness of ChitogenX's proprietary biopolymer matrix.NewswireCHITOGENX ANNOUNCES UP TO $4.35 MILLION PRIVATE PLACEMENT PURSUANT TO THE LISTED ISSUER EXEMPTIONChitogenX Inc. announced a best efforts private placement of up to $4.35 million through the sale of units at $0.225 each, alongside a concurrent non-brokered private placement for up to $1.75 million. The company intends to utilize the net proceeds to fund enrollment in its Rotator Cuff Tear Repair U.S. phase I/II clinical trial program and for general corporate purposes. The offering is led by Echelon Capital Markets as the lead agent and is scheduled to close around February 28, 2023.